Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Dean Investment Associates LLC

Dean Investment Associates LLC lessened its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 31.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,293 shares of the biopharmaceutical company's stock after selling 24,503 shares during the period. Dean Investment Associates LLC's holdings in Bristol-Myers Squibb were worth $3,071,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BMY. Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in Bristol-Myers Squibb in the 4th quarter worth approximately $34,000. Westend Capital Management LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at approximately $38,000. Tacita Capital Inc acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $39,000. Finally, M Holdings Securities Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $39,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Samit Hirawat bought 1,823 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded up $0.81 during trading hours on Tuesday, hitting $49.75. The stock had a trading volume of 3,953,295 shares, compared to its average volume of 12,942,967. The stock's fifty day simple moving average is $56.83 and its 200 day simple moving average is $56.64. The firm has a market capitalization of $101.23 billion, a price-to-earnings ratio of -11.24, a PEG ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.98%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of analyst reports. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday. Truist Financial increased their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Citigroup upped their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Finally, UBS Group dropped their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of "Hold" and an average target price of $58.13.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.